Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus

Ankit Gupta; Herbert F Jelinek; Hayder Al-Aubaidy

doi:10.1016/j.dsx.2016.09.003

Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus

Diabetes Metab Syndr. 2017 Jul-Sep;11(3):225-230. doi: 10.1016/j.dsx.2016.09.003. Epub 2016 Sep 15.

Authors

Ankit Gupta¹, Herbert F Jelinek², Hayder Al-Aubaidy³

Affiliations

¹ School of Medicine, University of Tasmania, Hobart, Australia.
² School of Community Health, Charles Sturt University, Albury, NSW, Australia.
³ School of Medicine, University of Tasmania, Hobart, Australia. Electronic address: H.AlAubaidy@utas.edu.au.

PMID: 27884496
DOI: 10.1016/j.dsx.2016.09.003

Abstract

This study summarizes major work which investigated the roles of glucagon like peptide-1 (GLP-1) and its receptor (GLP-1R); the use of GLP-1-R agonists and dipeptidyl peptidase 4 inhibitor in the management of type 2 diabetes mellitus. It focuses on the recent therapeutic development which has occurred in this field, and also discusses the potential treatments which can be discovered and implemented in the near future to design an effective therapy for type 2 diabetes mellitus.

Keywords: Dipeptidyl peptidase inhibitors; Glucagon like peptide-1; Type 2 diabetes mellitus.

Publication types

Review

MeSH terms

Amino Acid Sequence
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / genetics
Disease Management*
Glucagon-Like Peptide 1 / agonists*
Glucagon-Like Peptide 1 / physiology
Glucagon-Like Peptide-1 Receptor / agonists*
Glucagon-Like Peptide-1 Receptor / physiology
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Glucagon-Like Peptide 1